Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
4.11(c) 4.28(c) 4.1(c) 4.21(c) 4.31(c) Last
203 646 237 184 164 668 125 778 179 674 Volume
-10.85% +4.14% -4.21% +2.68% +2.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Sales 2021 - - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 161 M 161 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 24
Free-Float 85,3%
More Financials
Company
Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company’s lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton’s Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a... 
Sector
Biotechnology & Medical Research
Calendar
12/11 | 05:30pmPresentation
More about the company
All news about VIRACTA THERAPEUTICS, INC.
11/30INSIDER SELL : Viracta Therapeutics
MT
11/29Viracta Therapeutics Secures FDA Orphan Drug Designation for Lymphoma Combo Therapy
MT
11/29Viracta Therapeutics Gets FDA Orphan Drug Designation for Nana-val
DJ
11/29Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral ..
PR
11/11Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporat..
AQ
11/10VIRACTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/10Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/10Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporat..
PU
11/10SUNESIS : Q3 Earnings Snapshot
AQ
11/08Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and O..
AQ
11/05Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 Ameri..
AQ
11/05Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and O..
PU
11/05VIRACTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a ..
AQ
11/05Viracta Therapeutics, Inc. Secures $50 Million Credit Facility from Silicon Valley Bank..
CI
10/06VIRACTA THERAPEUTICS : Multinational trial expands Viracta's clinical-stage pipeline beyon..
PU
More news
News in other languages on VIRACTA THERAPEUTICS, INC.
11/29Viracta Therapeutics obtient de la FDA la désignation de médicament orphelin pour une t..
08/23Viracta Therapeutics récupère les droits exclusifs d'une combinaison thérapeutique pour..
07/21Viracta déclare que la FDA a donné son feu vert à un essai de phase 1b/2 dans les tumeu..
06/01Viracta Therapeutics lance un essai de phase 2 pour évaluer la combinaison Nanatinostat..
06/01Viracta Therapeutics dépose un dossier de 200 millions de dollars sur un plateau mixte.
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations
Chart VIRACTA THERAPEUTICS, INC.
Duration : Period :
Viracta Therapeutics, Inc. Technical Analysis Chart | VIRX | US92765F1084 | MarketScreener
Technical analysis trends VIRACTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 4,31 $
Average target price 33,50 $
Spread / Average Target 677%
EPS Revisions
Managers and Directors
Ivor Royston President, Chief Executive Officer & Director
Daniel R. Chevallard Secretary, Chief Operating & Financial Officer
Roger J. Pomerantz Chairman
Lisa Rojkjaer Chief Medical Officer
Ayman El-Guindy Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VIRACTA THERAPEUTICS, INC.-41.13%161
MODERNA, INC.170.27%114 479
LONZA GROUP AG24.16%58 572
IQVIA HOLDINGS INC.50.86%51 638
SEAGEN INC.-16.39%26 777
CELLTRION, INC.-43.31%23 611